Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Cancer Research UK Phase I/IIa Open Label, Dose Escalation and Expansion Trial of HMBD-001 (an Anti-HER3 Monoclonal Antibody) Given Intravenously as a Single Agent and in Combination in Patients With Advanced HER3 Positive Solid Tumours

NCT05057013 is registered in ClinicalTrials.gov with Cancer Research UK as lead sponsor.

NCT NCT05057013
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05057013 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Cancer Research UK Phase I/IIa Open Label, Dose Escalation and Expansion Trial of HMBD-001 (an Anti-HER3 Monoclonal Antibody) Given Intravenously as a Single Agent and in Combination in Patients With Advanced HER3 Positive Solid Tumours
Lead sponsor
Cancer Research UK
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 10, 2021
Completion date
November 30, 2025
Enrollment
81 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, castration-resistant prostate cancer, cervical cancer, endometrial cancer, gastric cancer, hepatocellular carcinoma (hcc), melanoma, non-small cell lung cancer (nsclc), oesophageal cancer, ovarian cancer, pancreatic cancer, ras wild type colorectal cancer, squamous cell cancer of the head and neck, triple negative breast cancer